Chinese tape maker Crown New Materials surges 787% in Shenzhen debut, creating paper billionaires 
Ekadashi kab hai in 2026: Rama on Nov 5, Devutthana on Nov 20, Papankusha on Oct 22 
Navy Court-Martials Captain, Lieutenant Commander Over INS Brahmaputra Capsizing 
K.C. Bokadia recalls the stars who never billed producers for staff 
SSC CGL Tier 1 Answer Key 2026 Is a Challenge Window, Not a Result 
ANEXT Bank Soft Launches Today As Singapore’s Newest Digital Wholesale Bank
An MoU is inked with Proxtera to jointly create and establish an open framework for all participating financial institutions, in...
Wasabi Technologies Doubles Down on APAC Expansion with Singapore Storage Region
25-Year year APAC industry veteran Michael King to lead Wasabi APAC Operations BOSTON & SINGAPORE--(BUSINESS WIRE)--Wasabi Technologies, the hot cloud...
Latest Data of InnoCare’s Orelabrutinib for the Treatment of SLE Presented at LBA Session of EULAR 2022
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that Professor Zhanguo Li, the leading PI, has presented...
Energy Transfer Signs LNG Sale and Purchase Agreement With China Gas
25-Year Agreement for LNG for Supply from Energy Transfer’s Lake Charles LNG Export Facility Represents First Long-Term LNG Contract Signed...
ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease
Daiichi Sankyo and AstraZeneca’s ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients...
Sino Jet Announces Carbon Neutrality Plan
HONG KONG SAR - Media OutReach - 5 June 2022 - On World Environment Day, 5th June 2022, Chinese business...
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate – – 87.5% of Responses Achieved in First...
Cubic Technology Launched to Provide Easier Rail Journeys for Queensland Commuters
Cubic Transportation Systems launches the first credit card and smart device-compatible gates on Queensland's Heavy Rail Network, giving more payment...
Kite Realty Group Trust to Present at NAREIT’s REITweek: 2022 Investor Conference
INDIANAPOLIS, June 03, 2022 (GLOBE NEWSWIRE) -- Kite Realty Group Trust (NYSE: KRG) announced today that it will present at...
Global Commercial Vehicle Surround View System Markets, 2021-2030: Revenue, Trends, Growth Opportunities, Competition, End Cases – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Commercial Vehicle Surround View System Market - Revenue, Trends, Growth Opportunities, Competition, COVID-19 Strategies, Regional Analysis and Future...
Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3...
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral...
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral...
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3...
OliX Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OLX101A in Patients with Hypertrophic Scars
SUWON, South Korea--(BUSINESS WIRE)--#ClinicalTrial--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the completion of patient...
